What is the treatment for Herpes Simplex Virus (HSV)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 4, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment for Herpes Simplex Virus (HSV)

Oral antiviral medications—valacyclovir, acyclovir, and famciclovir—are the mainstay of treatment for HSV infections, with valacyclovir preferred for most patients due to convenient dosing and equivalent efficacy. 1

First Clinical Episode Treatment

For initial genital herpes outbreaks, longer treatment courses are required to control the more extensive disease:

  • Valacyclovir 1 g orally twice daily for 7-10 days is the preferred first-line regimen 2, 1
  • Alternative regimens include:
    • Acyclovir 400 mg orally three times daily for 7-10 days 2, 1
    • Acyclovir 200 mg orally five times daily for 7-10 days 2, 1
    • Famciclovir 250 mg orally three times daily for 7-10 days 2, 1
  • Treatment may be extended beyond 10 days if healing is incomplete 2, 1

Recurrent Episodes Treatment

For recurrent outbreaks, shorter 5-day courses are effective:

  • Valacyclovir 500 mg orally twice daily for 5 days is the preferred episodic therapy 1, 3
  • Alternative regimens include:
    • Acyclovir 400 mg orally three times daily for 5 days 2, 1
    • Acyclovir 800 mg orally twice daily for 5 days 2, 1
    • Acyclovir 200 mg orally five times daily for 5 days 2, 1
    • Famciclovir 125 mg orally twice daily for 5 days 1, 3

Critical Timing Considerations

  • Start treatment during the prodromal period or within 1 day of lesion onset for maximum benefit 2, 1, 3
  • Treatment delayed beyond 72 hours has significantly reduced effectiveness 1, 3
  • Patients should be provided with medication or a prescription in advance to enable early self-initiated treatment 2

Suppressive Therapy

For patients with frequent recurrences (≥6 episodes per year), daily suppressive therapy is highly effective:

  • Valacyclovir 1 g orally once daily (preferred for convenience) 1
  • Alternative suppressive regimens:
    • Valacyclovir 500 mg orally once daily 1
    • Acyclovir 400 mg orally twice daily 2, 1
    • Famciclovir 250 mg orally twice daily 1
  • Suppressive therapy reduces recurrence frequency by ≥75% 2, 1
  • Suppressive therapy also reduces asymptomatic viral shedding and may reduce transmission risk to sexual partners 1, 3
  • After 1 year of continuous suppressive therapy, discontinue to reassess the patient's recurrence rate 2, 1

Special Populations

HIV-Infected Patients

  • HIV-infected patients require close monitoring and may need longer treatment courses than HIV-negative patients 1
  • Higher doses may be necessary: famciclovir 500 mg twice daily has demonstrated effectiveness in reducing recurrences and subclinical shedding in this population 1
  • Treatment failures occur more frequently, especially with shorter-course regimens 2

Pregnant Women

  • Standard antiviral dosing regimens are used during pregnancy 1
  • Ciprofloxacin is contraindicated during pregnancy 2, 1
  • No adverse effects of HSV antivirals on pregnancy outcomes have been reported 2

Critical Clinical Pitfalls to Avoid

  • Never use topical acyclovir—it is substantially less effective than oral therapy and should be avoided 2, 1
  • Do not expect antivirals to eradicate latent virus; they only control symptoms during active treatment 2, 1
  • Failing to provide advance prescriptions for episodic therapy prevents early self-initiated treatment 2
  • Not considering suppressive therapy in patients with frequent recurrences (≥6 per year) 1

Treatment Failure Considerations

If symptoms persist beyond expected healing time, consider:

  • Incorrect diagnosis or co-infection with another sexually transmitted disease 1
  • HIV infection (undiagnosed) 1
  • Poor medication adherence 1
  • Antiviral resistance (rare in immunocompetent patients)—treat with IV foscarnet 1

Counseling and Transmission Prevention

  • Patients should abstain from sexual activity when lesions or prodromal symptoms are present 2, 1
  • Encourage consistent condom use with new or uninfected partners 2, 1
  • Asymptomatic viral shedding occurs more frequently with HSV-2 than HSV-1 and in the first 12 months after infection 2
  • Suppressive therapy can reduce transmission risk to sexual partners 1, 3
  • Inform childbearing-aged women to notify healthcare providers about HSV infection during pregnancy 2

References

Guideline

Treatment for Herpes Simplex 2 (Genital Herpes)

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Treatment for Genital Herpes Simplex Virus Outbreaks

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.